Difference between revisions of "Azithromycin"

From Self-sufficiency
Jump to: navigation, search
m (1 revision)
(Brand names)
Line 1: Line 1:
{{drugbox | verifiedrevid = 321837379
+
{{drugbox | Watchedfields = changed
 +
| verifiedrevid = 321837379
 
|
 
|
| IUPAC_name = (2''R'',3''S'',4''R'',5''R'',8''R'',10''R'',11''R'',12''S'',13''S'',14''R'')-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo- 11-{[3,4,6-trideoxy-3-(dimethylamino)-β-<small>D</small>-''xylo''-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadec-13-yl 2,6-dideoxy-3-''C''-methyl-3-''O''-methyl-α-<small>L</small>-''ribo''-hexopyranoside
+
| IUPAC_name = (2''R'',3''S'',4''R'',5''R'',8''R'',10''R'',11''R'',12''S'',13''S'',14''R'')-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo- 11-{[3,4,6-trideoxy-3-(dimethylamino)-β-<small>D</small>-''xylo''-]oxy}-1-oxa-6-azacyclopentadec-13-yl 2,6-dideoxy-3-''C''-methyl-3-''O''-methyl-α-<small>L</small>-''ribo''-hexopyranoside
 
| image = Azithromycin structure.svg
 
| image = Azithromycin structure.svg
 
| width = 200
 
| width = 200
Line 35: Line 36:
 
Azithromycin is one of the world's best-selling antibiotics,<ref>[http://www.wipo.int/sme/en/case_studies/pliva.htm] </ref> sold in the [[United States]] under the name '''Zithromax''', and under a variety of brand names and generic labels worldwide. It is derived from [[erythromycin]]; however, it differs chemically from erythromycin in that a [[methyl]]-substituted [[nitrogen]] [[atom]] is incorporated into the [[lactone]] ring, thus making the lactone ring 15-membered.  
 
Azithromycin is one of the world's best-selling antibiotics,<ref>[http://www.wipo.int/sme/en/case_studies/pliva.htm] </ref> sold in the [[United States]] under the name '''Zithromax''', and under a variety of brand names and generic labels worldwide. It is derived from [[erythromycin]]; however, it differs chemically from erythromycin in that a [[methyl]]-substituted [[nitrogen]] [[atom]] is incorporated into the [[lactone]] ring, thus making the lactone ring 15-membered.  
  
Azithromycin is used to treat or  prevent certain [[bacterial infections]], most often those causing [[Otitis media|middle ear infections]], [[tonsillitis]], throat infections, [[laryngitis]], [[bronchitis]], [[pneumonia]], [[Typhoid]], and [[sinusitis]].  In recent years it has primarily been used to prevent bacterial infections in infants and those with weaker [[immune systems]]. It is also effective against certain [[urinary tract infections]] and [[venereal diseases]], such as [[non-gonococcal urethritis]], [[chlamydia infection|chlamydia]], [[gonorrhea]] and cervicitis. Recent studies have also indicated it to be effective against late-onset [[asthma]], but these findings are controversial and not widely accepted.<ref>{{cite journal | author=Hahn,D.L.| title=Treatment of pneumoniae infection in adult asthma: A before -after trial | journal=J Fam Pract. | year=1995 | volume=41 | pages=345–351 | pmid=7561707 | issue=4}}</ref><ref>{{cite journal | author=JD Klausner, D Passaro, J Rosenberg, WL Thacker, DF Talkington, SB Werner, DJ Vugia| title=Enhanced control of an outbreak of Mycoplasma pneumoniae pneumonia with azithromycin prophylaxis | journal=Journal of Infectious Diseases | year=1998 | volume=177 | pages=161–166 | doi=10.1086/513818 | pmid=9419183 | issue=1}}</ref> Note that whereas the traditional zpack (500mg + 4 days of 250 mg) may be used in some instances, particularly for strep in pediatric cases, for adults over 88 pounds, the PDR calls for five (5) days of 500mg for strep throat, and yet the pediatric lesser dose is commonly mis-prescribed.<ref>Physicians Desk Reference, Azithromycin, 2009.</ref>
+
Azithromycin is used to treat or  prevent certain [[bacterial infections]], most often those causing [[Otitis media|middle ear infections]], [[tonsillitis]], [[throat infections]], [[laryngitis]], [[bronchitis]], [[pneumonia]], [[Typhoid]], and [[sinusitis]].  In recent years it has primarily been used to prevent bacterial infections in infants and those with weaker [[immune systems]]. It is also effective against certain [[venereal diseases]], such as [[non-gonococcal urethritis]], [[chlamydia infection|chlamydia]], [[gonorrhea]] and cervicitis. Recent studies have also indicated it to be effective against late-onset [[asthma]], but these findings are controversial and not widely accepted.<ref>{{cite journal | author=Hahn,D.L.| title=Treatment of Chlamydia pneumoniae infection in adult asthma: A before-after trial | journal=J Fam Pract. | year=1995 | volume=41 | pages=345–351 | pmid=7561707 | issue=4}}</ref><ref>{{cite journal | author=JD Klausner, D Passaro, J Rosenberg, WL Thacker, DF Talkington, SB Werner, DJ Vugia| title=Enhanced control of an outbreak of [[Mycoplasma pneumoniae pneumonia]] with azithromycin prophylaxis | journal=Journal of Infectious Diseases | year=1998 | volume=177 | pages=161–166 | doi=10.1086/513818 | pmid=9419183 | issue=1}}</ref> Note that whereas the traditional zpack (500mg + 4 days of 250 mg) may be used in some instances, particularly for strep in pediatric cases, for adults over 88 pounds, the PDR calls for five (5) days of 500mg for strep throat, and yet the pediatric lesser dose is commonly mis-prescribed.<ref>Physicians Desk Reference, Azithromycin, 2009.</ref>
  
 
== Etymology ==
 
== Etymology ==
Line 49: Line 50:
  
 
=== Brand names ===
 
=== Brand names ===
[[File:Azithromycin 250mg.jpg|thumb|Azithromycin 250 mg capsules ("zpack") from Serbia]]
+
[[File:Azithromycin 250mg.jpg|thumb|Azithromycin 250 mg capsules ("zpack") from Ukraine]]
Azithromycin is sold under brand names APO-Azithromycin and Co Azithromycin in Canada; Zithromax in Finland, Italy, the United Kingdom, the United States, Australia, Portugal, South Africa, Canada, Thailand, Malaysia, Lebanon, Egypt and Belgium; Hemomicin in Serbia; Zithromac in Japan; Vinzam/Zitromax in Spain; Zmax; Sumamed in Bulgaria, Croatia, the Czech Republic, the Russian Federation, Slovakia and Slovenia; Azitrox in Czech Republic and Romania; Amixef in Peru; ATM, Aztrin, Azigard, Zitrocin, Azibiot, Azifine, AziCip, Azi Sandoz, Aziswift, AZORTA & AZEE, Azithral,Azibest, ZADY in India;<ref>[http://www.cipla.com/admin.php?mode=cat&action=disp&parentid=2&catid=3]</ref> EZONEX of PharmaHealth, Azithrocin in Bangladesh, Tablets Winzith, zetro capsule and suspension; Saver (Laboratorios Elmer) in Venezuela
+
Azithromycin is sold under brand names APO-Azithromycin and Co Azithromycin in Canada; Zithromax in Finland, Italy, the United Kingdom, the United States, Australia, Portugal, South Africa, Canada, Thailand, Malaysia, Lebanon, Egypt, Belgium and Greece; Hemomicin in Serbia; Zithromac in Japan; Vinzam/Zitromax in Spain; Zmax; Sumamed in Bulgaria, Croatia, the Czech Republic, the Russian Federation, Slovakia and Slovenia; Azitrox in Czech Republic and Romania; Amixef in Peru;Simpli-3(Beacon Pharma) in Bangladesh.
 +
also is available in Egypt in new concentration 600 mg oral taplet not capsule by Delta Pharma. Azithromycin 500mg is available to buy over the counter as Clamelle in the UK providing the customer can provide evidence of a positive chlamydia test. <ref>http://www.chemist.net/sexual-health-chlamydia-testing-kits/clamelle/clamelle-azithromycin-500mg-tablets-chlamydia-treatment-pd-9288.html</ref>
  
 
== Mechanism of action ==
 
== Mechanism of action ==
Line 56: Line 58:
  
 
== Microbiology ==
 
== Microbiology ==
Azithromycin has a similar antimicrobial spectrum as [[erythromycin]], but is more effective against certain [[gram-negative]] bacteria, particularly ''[[Haemophilus influenzae]]''. Azithromycin resistance has been described <ref>{{cite journal | author=Chisholm SA, Neal TJ, Alawattegama AB, ''et al.'' | title=Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales | journel=J Antimicrob Chemother | year=2009 | volume=64 | issue=2 | pages=353&ndash;8 | pmid=19468025 | doi=10.1093/jac/dkp188 | journal=The Journal of antimicrobial chemotherapy }}</ref> and is [[endemic (epidemiology)|endemic]] in many areas.
+
Azithromycin has a similar antimicrobial spectrum as [[erythromycin]], but is more effective against certain [[Gram-negative]] bacteria, particularly ''[[Haemophilus influenzae]]''. Azithromycin resistance has been described <ref>{{cite journal | author=Chisholm SA, Neal TJ, Alawattegama AB, ''et al.'' | title=Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales | journel=J Antimicrob Chemother | year=2009 | volume=64 | issue=2 | pages=353&ndash;8 | pmid=19468025 | doi=10.1093/jac/dkp188 | journal=The Journal of antimicrobial chemotherapy }}</ref> and is [[endemic (epidemiology)|endemic]] in many areas.
  
 
Azithromycin has been most effective against isolates of the following microorganisms:  
 
Azithromycin has been most effective against isolates of the following microorganisms:  
Line 89: Line 91:
  
 
== Side effects ==
 
== Side effects ==
Most common side effects are gastrointestinal; diarrhea (5%), nausea (3%), abdominal pain (3%) and vomiting.  Fewer than 1% of patients stop taking the drug due to side effects. Serious allergic reactions, nervousness, dermatologic reactions, and fatalities have been reported. As with all antimicrobial agents, [[pseudomembranous colitis]] can occur during and up to several weeks after azithromycin therapy. This drug may interfere with the effectiveness of birth control pills; other forms of contraception may be required during the treatment period.
+
Most common side effects are gastrointestinal; diarrhea (5%), nausea (3%), abdominal pain (3%) and vomiting.  Fewer than 1% of patients stop taking the drug due to side effects. Nervousness, dermatologic reactions and anaphylaxis have been reported. As with all antimicrobial agents, [[pseudomembranous colitis]] can occur during and up to several weeks after azithromycin therapy. This drug may interfere with the effectiveness of birth control pills; other forms of contraception may be required during the treatment period. Azithromycin suspension has an objectionable taste, so can be difficult to administer to young children (i.e., 2-5 years), who may spit it out.
  
Azithromycin suspension has an objectionable taste, so can be difficult to administer to young children (i.e. 2 - 5 years) who may spit it out.
+
Occasional patients have developed cholestatic hepatitis or delirium. Accidental intravenous overdosage in an infant caused severe heart block, resulting in residual encephalopathy.<ref>Tilelli JA, Smith KM, Pettignano R. Life-threatening bradyarrhythmia after massive azithromycin overdose. Pharmacotherapy 26: 147-150, 2006.</ref><ref>R. Baselt, ''Disposition of Toxic Drugs and Chemicals in Man'', 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 132-133.</ref>
  
 
== References ==
 
== References ==
Line 116: Line 118:
 
[[it:Azitromicina]]
 
[[it:Azitromicina]]
 
[[hu:Azitromicin]]
 
[[hu:Azitromicin]]
 +
[[ka:აზიმაკი]]
 
[[nl:Azithromycine]]
 
[[nl:Azithromycine]]
 
[[ja:アジスロマイシン]]
 
[[ja:アジスロマイシン]]

Revision as of 10:42, 15 September 2010

Azithromycin
200px
200px
Systematic (IUPAC) name
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo- 11-{[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-]oxy}-1-oxa-6-azacyclopentadec-13-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranoside
Clinical data
Pregnancy
category
  • AU: B1
  • US: B (No risk in non-human studies)
Routes of
administration
Oral (capsule or suspension), intravenous, ophthalmic
Pharmacokinetic data
Bioavailability 38% for 250 mg capsules
Metabolism Hepatic
Biological half-life 68 hours
Excretion Biliary, renal (4.5%)
Identifiers
CAS Number 83905-01-5
ATC code J01FA10 (WHO) S01AA26
PubChem CID 55185
DrugBank APRD00397
ChemSpider 10482163
Synonyms 9-deoxy-9a-aza-9a-methyl-9a-homoerythromycin A
Chemical data
Formula C38H72N2O12
Molar mass 748.984 g·mol−1[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
  (verify)
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Azithromycin is an azalide, a subclass of macrolide antibiotics. Azithromycin is one of the world's best-selling antibiotics,[1] sold in the United States under the name Zithromax, and under a variety of brand names and generic labels worldwide. It is derived from erythromycin; however, it differs chemically from erythromycin in that a methyl-substituted nitrogen atom is incorporated into the lactone ring, thus making the lactone ring 15-membered.

Azithromycin is used to treat or prevent certain bacterial infections, most often those causing middle ear infections, tonsillitis, throat infections, laryngitis, bronchitis, pneumonia, Typhoid, and sinusitis. In recent years it has primarily been used to prevent bacterial infections in infants and those with weaker immune systems. It is also effective against certain venereal diseases, such as non-gonococcal urethritis, chlamydia, gonorrhea and cervicitis. Recent studies have also indicated it to be effective against late-onset asthma, but these findings are controversial and not widely accepted.[2][3] Note that whereas the traditional zpack (500mg + 4 days of 250 mg) may be used in some instances, particularly for strep in pediatric cases, for adults over 88 pounds, the PDR calls for five (5) days of 500mg for strep throat, and yet the pediatric lesser dose is commonly mis-prescribed.[4]

Etymology

Azithromycin's name is derived from the azane-substituent and erythromycin.

History

A team of researchers at the Croatian pharmaceutical company Pliva, Gabrijela Kobrehel, Gorjana Radobolja-Lazarevski and Zrinka Tamburašev led by Dr. Slobodan Đokić, discovered azithromycin in 1980. It was patented in 1981, and was later found by Pfizer's scientists while going through patent documents. In 1986 Pliva and Pfizer signed a licensing agreement which gave Pfizer exclusive rights for the sale of azithromycin in Western Europe and the United States. Pliva brought their azithromycin on the market in Central and Eastern Europe under the brand name of Sumamed in 1988, Pfizer Zithromax in 1991, and Zentiva Azitrox. After several years, the U.S. Food and Drug Administration (FDA) approved AzaSite, an ophthalmic formulation of azithromycin, for the treatment of eye infections. AzaSite is currently marketed in the US by Inspire Pharmaceuticals.

Available forms

Azithromycin is commonly administered in tablet or oral suspension (a one-dose version was made available in 2005). It is also available for intravenous injection and in a 1% ophthalmic solution. Tablets come in 250 mg and 500 mg doses. Oral suspension comes in 100 mg/5 mL and 200 mg/5 mL strengths. The 250 mg tablets are often dispensed in packages of six and commonly referred to as a "Z-Pak," whereas the 500 mg tablets are commonly available commercially in a pack of three tablets, or "Tri-Pak," intended as a three-day treatment. A common dose of oral azithromycin therapy consists of a "double dose" of medication on the first day of treatment and subsequent treatment for four or five additional days. With the "Z-Pak," this means two 250 mg tablets (a total of 500 mg) on the first day and one 250 mg tablet once daily for the next four days.

Pfizer brand-name (e.g., Zithromax) azithromycin tablets are mottled pink, unscored, film-coated, modified-oval-shaped tablets containing azithromycin monohydrate equivalent to 250 mg or 500 mg azithromycin and the following inactive ingredients: butylated hydroxytoluene, calcium phosphate, carmine, colloidal silicon dioxide, FD&C red # 40 lake, FD&C yellow # 6 lake, hypromellose (2910, 15cP), lactose monohydrate, magnesium stearate, pregelatinized starch, sodium lauryl sulfate, talc, titanium dioxide and triacetin. The 250 mg tablets have the following appearance: They are mottled pink, of a modified-oval-shape, and have "Pfizer" engraved into one side with "306" engraved into the other. The 500 mg tablet is similar in appearance with the exception of its relative size and "ZTM500" engraved onto one side with "Pfizer" on the reverse. As with all medications, generic azithromycin tablets produced by companies other than Pfizer without the Zithromax brand name may have different appearances. For instance, the generic azithromycin sold under the Greenstone brand is pink, with the hexagonal "G" Greenstone, Ltd. logo engraved on one side and the numerals 3060 on the other. Greenstone, Ltd. is a subsidiary of Pfizer. The Novartis subsidiary Sandoz ships azithromycin as white oval tablets stamped with "GGD6" (250 mg) or "GGD8" (500 mg). A generic azithromycin made by Wockhardt is made as white oval tablets stamped with "W961" (250 mg).For this drug USP Reference standards are available(www.usp.org)

Brand names

File:Azithromycin 250mg.jpg
Azithromycin 250 mg capsules ("zpack") from Ukraine

Azithromycin is sold under brand names APO-Azithromycin and Co Azithromycin in Canada; Zithromax in Finland, Italy, the United Kingdom, the United States, Australia, Portugal, South Africa, Canada, Thailand, Malaysia, Lebanon, Egypt, Belgium and Greece; Hemomicin in Serbia; Zithromac in Japan; Vinzam/Zitromax in Spain; Zmax; Sumamed in Bulgaria, Croatia, the Czech Republic, the Russian Federation, Slovakia and Slovenia; Azitrox in Czech Republic and Romania; Amixef in Peru;Simpli-3(Beacon Pharma) in Bangladesh. also is available in Egypt in new concentration 600 mg oral taplet not capsule by Delta Pharma. Azithromycin 500mg is available to buy over the counter as Clamelle in the UK providing the customer can provide evidence of a positive chlamydia test. [5]

Mechanism of action

Azithromycin prevents bacteria from growing by interfering with their protein synthesis. Azithromycin binds to the 50S subunit of the bacterial ribosome, and thus inhibits translation of mRNA. Nucleic acid synthesis is not affected.

Microbiology

Azithromycin has a similar antimicrobial spectrum as erythromycin, but is more effective against certain Gram-negative bacteria, particularly Haemophilus influenzae. Azithromycin resistance has been described [6] and is endemic in many areas.

Azithromycin has been most effective against isolates of the following microorganisms:

It is notably ineffective against MRSA.

Azithromycin has been shown to be effective against malaria when used in combination with artesunate or quinine; the optimal dose for this is not yet known.[7]

Pharmacokinetics

Unlike erythromycin, azithromycin is acid-stable and can therefore be taken orally with no need of protection from gastric acids. It is readily absorbed, but its absorption is greater on an empty stomach. Time to peak concentration in adults is 2.1 to 3.2 hours for oral dosage forms and 1 to 2 hours for intravenous (IV) forms. Due to the high concentration in phagocytes, azithromycin is actively transported to the site of infection. During active phagocytosis, large concentrations of azithromycin are released. The concentration of azithromycin in the tissues can be over 50 times higher than in plasma. This is due to ion trapping and the high lipid solubility.

Azithromycin's half-life allows a large single dose to be administered and yet maintain bacteriostatic levels in the infected tissue for several days. The new extended-release formulation of azithromycin "Zmax" is a liquid oral suspension that releases the drug in a single 2-g dose. With the macrolide technology of Zmax, this allows the drug to bypass the stomach, reducing gastrointestinal side effects of high-dose azithromycin.

Metabolism

According to Davis' Drug Guide for Nurses, following a single 500 mg dose, the half-life of azithromycin is 11-14 hours. The longer half-life of 68 hours is achieved only when multiple doses are consumed, allowing a "steady state" of medication in the body.

Biliary excretion of azithromycin, predominantly unchanged, is a major route of elimination. Over the course of a week, approximately 6% of the administered dose appears as unchanged drug in urine.

Side effects

Most common side effects are gastrointestinal; diarrhea (5%), nausea (3%), abdominal pain (3%) and vomiting. Fewer than 1% of patients stop taking the drug due to side effects. Nervousness, dermatologic reactions and anaphylaxis have been reported. As with all antimicrobial agents, pseudomembranous colitis can occur during and up to several weeks after azithromycin therapy. This drug may interfere with the effectiveness of birth control pills; other forms of contraception may be required during the treatment period. Azithromycin suspension has an objectionable taste, so can be difficult to administer to young children (i.e., 2-5 years), who may spit it out.

Occasional patients have developed cholestatic hepatitis or delirium. Accidental intravenous overdosage in an infant caused severe heart block, resulting in residual encephalopathy.[8][9]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links

de:Azithromycin

dv:އެޒިތުރޯމައިސިން es:Azitromicina fa:آزیترومایسین fr:Azithromycine hr:Sumamed it:Azitromicina hu:Azitromicin ka:აზიმაკი nl:Azithromycine ja:アジスロマイシン no:Azitromycin pl:Azytromycyna pt:Azitromicina ro:Azitromicină ru:Азитромицин sl:Azitromicin fi:Atsitromysiini th:อะซิโทรมัยซิน

zh:阿奇霉素
  1. [1]
  2. Hahn,D.L. (1995). "Treatment of Chlamydia pneumoniae infection in adult asthma: A before-after trial". J Fam Pract. 41 (4): 345–351. PMID 7561707. 
  3. JD Klausner, D Passaro, J Rosenberg, WL Thacker, DF Talkington, SB Werner, DJ Vugia (1998). "Enhanced control of an outbreak of Mycoplasma pneumoniae pneumonia with azithromycin prophylaxis". Journal of Infectious Diseases. 177 (1): 161–166. doi:10.1086/513818. PMID 9419183. 
  4. Physicians Desk Reference, Azithromycin, 2009.
  5. http://www.chemist.net/sexual-health-chlamydia-testing-kits/clamelle/clamelle-azithromycin-500mg-tablets-chlamydia-treatment-pd-9288.html
  6. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  7. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  8. Tilelli JA, Smith KM, Pettignano R. Life-threatening bradyarrhythmia after massive azithromycin overdose. Pharmacotherapy 26: 147-150, 2006.
  9. R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 132-133.